

**Table 4.3**  
**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for CT Participants Who Did Not Report a Prevalent Condition at Baseline**

Data as of: February 28, 2017; Events through February 28, 2017

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number randomized</b>	68132	9188	14661	31389	12894
<b>Mean follow-up (months)</b>	185.7	202.1	198.9	186.0	158.1
<b>Hospitalizations</b>					
Ever	49922 (4.74%)	5485 (3.54%)	9725 (4.00%)	23996 (4.93%)	10716 (6.31%)
Two or more	36186 (3.43%)	3489 (2.25%)	6574 (2.71%)	17790 (3.66%)	8333 (4.91%)
<b>Other</b>					
DVT <sup>1</sup>	1853 (0.18%)	137 (0.09%)	300 (0.13%)	908 (0.19%)	508 (0.31%)
Pulmonary embolism	1435 (0.14%)	130 (0.08%)	252 (0.10%)	745 (0.15%)	308 (0.18%)
Diabetes (treated)	10823 (1.07%)	1609 (1.07%)	2446 (1.04%)	5119 (1.10%)	1649 (1.02%)
Gallbladder disease <sup>2,3</sup>	5248 (1.15%)	746 (1.07%)	1195 (1.15%)	2463 (1.21%)	844 (1.05%)
Hysterectomy	3468 (0.56%)	516 (0.57%)	884 (0.58%)	1621 (0.57%)	447 (0.47%)
Glaucoma <sup>3</sup>	7565 (1.44%)	744 (0.96%)	1457 (1.23%)	3662 (1.54%)	1702 (1.86%)
Osteoporosis <sup>3</sup>	14695 (2.85%)	1450 (1.88%)	2635 (2.24%)	7142 (3.07%)	3468 (3.92%)
Osteoarthritis <sup>4</sup>	21992 (3.25%)	3470 (2.86%)	5256 (3.03%)	9986 (3.40%)	3280 (3.75%)
Rheumatoid arthritis <sup>3</sup>	4009 (0.76%)	538 (0.70%)	866 (0.74%)	1822 (0.77%)	783 (0.83%)
Intestinal polyps	17690 (1.81%)	2645 (1.77%)	4297 (1.86%)	8334 (1.86%)	2414 (1.61%)
Lupus	1106 (0.11%)	152 (0.10%)	256 (0.11%)	519 (0.11%)	179 (0.11%)
Kidney stones <sup>3,4</sup>	1877 (0.36%)	241 (0.31%)	379 (0.32%)	898 (0.38%)	359 (0.38%)
Cataracts <sup>3,4</sup>	21571 (4.54%)	1468 (1.90%)	3731 (3.20%)	11650 (5.43%)	4722 (7.09%)
Hypertension treated w/pills	26654 (3.53%)	3654 (2.90%)	5981 (3.20%)	12451 (3.70%)	4568 (4.32%)
COPD <sup>5</sup>	3443 (0.97%)	369 (0.72%)	791 (0.99%)	1831 (1.13%)	452 (0.78%)
Macular degeneration <sup>6</sup>	8005 (1.24%)	529 (0.56%)	1227 (0.83%)	4203 (1.41%)	2046 (2.02%)
Alzheimer's disease <sup>6</sup>	5980 (0.93%)	233 (0.25%)	663 (0.45%)	3120 (1.05%)	1964 (1.94%)
Parkinson's disease <sup>6</sup>	971 (0.15%)	71 (0.08%)	187 (0.13%)	539 (0.18%)	174 (0.17%)

<sup>1</sup> Inpatient DVT only.

<sup>2</sup> "Gallbladder disease" includes self-reports of both hospitalized and non-hospitalized events.

<sup>3</sup> Data not collected for the WHI Extension Studies 2005-2020.

<sup>4</sup> These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>5</sup> Data only collected during the WHI Extension Study 2010-2020.

<sup>6</sup> Data only collected during the WHI Extension Studies 2005-2020.

**Table 4.3 (continued)**  
**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for CT Participants Who Did Not Report a Prevalent Condition at Baseline**

Data as of: February 28, 2017; Events through February 28, 2017

Outcomes	Race/Ethnicity					
	Am Indian/ Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/ Latina	White	Unknown
<b>Number randomized</b>	292	1519	6983	2875	55525	938
<b>Mean follow-up (months)</b>	166.9	177.1	170.0	158.9	189.6	171.6
<b>Hospitalizations</b>						
Ever	201 (4.95%)	854 (3.81%)	4754 (4.81%)	1615 (4.24%)	41861 (4.77%)	637 (4.75%)
Two or more	150 (3.69%)	506 (2.26%)	3345 (3.38%)	996 (2.62%)	30765 (3.51%)	424 (3.16%)
<b>Other</b>						
DVT <sup>1</sup>	7 (0.18%)	10 (0.04%)	213 (0.22%)	36 (0.10%)	1567 (0.18%)	20 (0.15%)
Pulmonary embolism	7 (0.17%)	6 (0.03%)	143 (0.15%)	23 (0.06%)	1242 (0.14%)	14 (0.10%)
Diabetes (treated)	51 (1.37%)	277 (1.31%)	1529 (1.73%)	571 (1.59%)	8232 (0.97%)	163 (1.29%)
Gallbladder disease <sup>2,3</sup>	22 (1.31%)	86 (0.81%)	420 (0.85%)	243 (1.45%)	4403 (1.18%)	74 (1.20%)
Hysterectomy	8 (0.45%)	52 (0.36%)	233 (0.54%)	124 (0.58%)	3018 (0.57%)	33 (0.42%)
Glaucoma <sup>3</sup>	40 (1.85%)	153 (1.35%)	1005 (1.96%)	338 (1.59%)	5930 (1.37%)	99 (1.47%)
Osteoporosis <sup>3</sup>	66 (3.04%)	389 (3.49%)	909 (1.71%)	639 (3.12%)	12483 (2.96%)	209 (3.11%)
Osteoarthritis <sup>4</sup>	95 (3.73%)	519 (3.14%)	2036 (3.31%)	972 (3.62%)	18056 (3.22%)	314 (3.60%)
Rheumatoid arthritis <sup>3</sup>	32 (1.55%)	74 (0.66%)	682 (1.33%)	357 (1.70%)	2787 (0.65%)	77 (1.13%)
Intestinal polyps	80 (2.13%)	355 (1.73%)	1860 (2.02%)	622 (1.71%)	14541 (1.78%)	232 (1.88%)
Lupus	8 (0.20%)	16 (0.07%)	143 (0.15%)	54 (0.14%)	870 (0.10%)	15 (0.11%)
Kidney stones <sup>3,4</sup>	15 (0.71%)	47 (0.42%)	190 (0.35%)	100 (0.48%)	1501 (0.35%)	24 (0.35%)
Cataracts <sup>3,4</sup>	92 (4.68%)	428 (4.21%)	2002 (4.10%)	828 (4.10%)	17928 (4.62%)	293 (4.72%)
Hypertension treated w/pills	105 (3.86%)	554 (3.58%)	2247 (4.46%)	1139 (3.98%)	22284 (3.44%)	325 (3.53%)
COPD <sup>5</sup>	19 (1.33%)	35 (0.43%)	258 (0.73%)	97 (0.65%)	2994 (1.03%)	40 (0.82%)
Macular degeneration <sup>6</sup>	27 (0.99%)	102 (0.72%)	391 (0.63%)	201 (0.80%)	7210 (1.36%)	74 (0.85%)
Alzheimer's disease <sup>6</sup>	22 (0.81%)	93 (0.65%)	509 (0.82%)	199 (0.80%)	5094 (0.96%)	63 (0.72%)
Parkinson's disease <sup>6</sup>	3 (0.11%)	17 (0.12%)	64 (0.10%)	28 (0.11%)	847 (0.16%)	12 (0.14%)

<sup>1</sup> Inpatient DVT only.

<sup>2</sup> "Gallbladder disease" includes self-reports of both hospitalized and non-hospitalized events.

<sup>3</sup> Data not collected for the WHI Extension Studies 2005-2020.

<sup>4</sup> These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>5</sup> Data only collected during the WHI Extension Study 2010-2020.

<sup>6</sup> Data only collected during the WHI Extension Studies 2005-2020.